Media Release – Industry calls for Medical Technologies and Pharmaceuticals Innovation Hub

Media Release – Monday 20th November 2017 At its Annual General Meeting today, BioMelbourne Network will launch a pre-budget submission calling for the Victorian Government to invest in a Medical Technologies and Pharmaceuticals Innovation Hub in Melbourne. The Hub…

Read More

BioMelbourne Network submission to the Policy Consultation Paper – Visa Simplification: Transforming Australia’s Visa System

“Australia’s visa system must remain globally competitive to attract talent to build future industries and transition to a knowledge-led economy” Health is a global market and access to global talent is critical for healthcare innovation. Companies need to…

Read More

September 2017 – Pharmaceutical Manufacturing: Driving Competitive Advantage for Victoria

Continued Discussions : Pharmaceutical Manufacturing: Driving Competitive Advantage for Victoria BioMelbourne Network convened a roundtable with Minister Wade Noonan, Minister Philip Dalidakis and 14 pharmaceutical and biotechnology companies who currently manufacture or develop products for manufacture in Victoria…

Read More

Joint Statement on Skilled Migration Visa Changes

Restoration on skilled visas welcomed across medical technology, biotechnology and pharmaceutical sector. The restoration of key occupations for the medical technology, research and pharmaceutical sector to the skilled migration visa list has been welcomed by six representative organisations.…

Read More

BioMelbourne Network Welcomes Revisions to Skilled Migration Visas

Revisions to the skilled migration list have been welcomed by many BioMelbourne Network members across the biotechnology, medical technology and pharmaceutical sector. The restoration of occupations such as life scientist, biotechnologist, CEO/General Manager, and biochemist to the Medium…

Read More

May 2017 – Department of Immigration Roundtable Discussion

BioMelbourne Network CEO, Dr Krystal Evans attended a technology industries roundtable discussion with the Department of Immigration and the Department of Industry regarding skilled migration and the decision to abolish the 457 visa program. The medical technology, biotechnology and…

Read More

Joint statement on the Research & Development Tax Incentive 18 April 2017

Don’t rip the guts out of Australian medical research commercialisation Commercialisation of Australian medical research is under serious threat if the package of measures put by the ‘Ferris, Finkel, Fraser’ Review of the Research & Development (R&D) Tax…

Read More

December 2016 – Meeting with the Hon Jill Hennessy, Minister for Health

Dr Krystal Evans met with the Hon Jill Hennessy’s office and had a detailed discussion about the more specific impact of the proposed cap on clinical trials in Victoria. BioMelbourne Network is aware that State Ministers have formally communicated…

Read More

December 2016 – CfM Future Focus Group on Future Biotech Skills in Melbourne

BioMelbourne Network CEO Dr Krystal Evans and interim CEO Lusia Guthrie recently participated in a meeting for the Committee for Melbourne Future Focus Group  project on Future Biotech Skills in Melbourne.  This project will is about ensuring our…

Read More

November 2016 – Meeting with the Hon Greg Hunt, Minister for Industry, Innovation and Science

BioMelbourne Network CEO, Dr Krystal Evans participated in a roundtable discussion with Minister Hunt and industry leaders, representatives from Medicines Australia, AusBiotech, Research Australia, MTAA and BioMelbourne Network was a highly constructive session discussing the Review of the R&D…

Read More

November 2016 – BioMelbourne Network response to proposed changes to R&D Tax Incentive

BioMelbourne Network wrote to the Hon Greg Hunt – Minister of Industry, Innovation and Science, on behalf of our members to express serious concern over the impact of proposed changes to the R&D Tax incentive on the biotechnology,…

Read More

October 2016 – Have your say on the R&D Tax Incentive Review Paper

Deadline: 28th October 2016 The R&D Tax Incentive Review paper including a proposed $2M cap on the annual cash refund payable under the R&D Tax Incentive. BioMelbourne Network does not support this proposed change to the R&D Tax Incentive which…

Read More


News & opinion

Member Directory